Bayer and Iambic Therapeutics Inc., a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced a drug discovery collaboration in which Bayer will discover new medicines using Iambic’s AI-driven platform. The collaboration is focused on small molecule discovery.
University College Dublin’s NAX Bioscience and Trinity College Dublin’s Imragen recognised for novel genomics-driven technologies and commercial potential
Sonothera closes their Series B financing to advance clinical development of ultrasound mediated non-viral genetic medicines.
Collaboration seeks to accelerate translation and development of stem cell-derived pancreatic cells
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
